Today Stories

On-shore manufacturing facility based in Melbourne, Australia, expected to produce up to 100 million mRNA respiratory vaccine doses annually CAMBRIDGE, MA / ACCESSWIRE / March 23, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the finalization of a strategic partnership with the Australian Federal Government to establish a state-of-the-art, domestic mRNA vaccine manufacturing facility in Australia. This finalizes the agreement in principle with the Australian Federal Government announced in December 2021. "We are delighted to reach this milestone with the Australian Government and finalize our first on-shore manufacturing agreement," said Stéphane Bancel, Chief Executive Officer of Moderna. "The Austral…

mRNA-1230 is a combination respiratory vaccine candidate against SARS-CoV-2 virus, influenza virus and respiratory syncytial virus (RSV) mRNA-1287 is a vaccine candidate against the four endemic human coronaviruses (HCoV-229E, -NL63, -OC43 and -HKU1) CAMBRIDGE, MA / ACCESSWIRE / March 22, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its mRNA pipeline with two new development programs. This announcement reflects the Company's commitment to expanding its portfolio by building on Moderna's experience with Spikevax®, its COVID-19 vaccine. The development programs include a combination respiratory vaccine candidate and a new program against all four of the endemic human coronaviruses…

SUZHOU, China, March 22, 2022, Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has established a global clinical collaboration with Bristol Myers Squibb to evaluate the combination of TST001, an investigational humanized monoclonal antibody targeting Claudin18.2 developed by Transcenta, with Opdivo® (nivolumab), Bristol Myers Squibb's anti-PD-1 therapy, for the treatment of patients with unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction cancer (GC/GEJ). This collaboration includes two global phase I/II open-label, multi-center studies, one to be held in the U.S. an…

- Creation of new company combines strengths of three leading value-based care specialists- Execution on strategic expansion along the renal care continuum significantly expands Fresenius Medical Care's total addressable market in the U.S. from around $50 billion to around $170 billion- Establishing independent and integrated value-based care offering in-line with FME25 plan of refining and further growing future Care Delivery segment in the U.S. Fresenius Medical Care, the world's leading provider of products and services for individuals with kidney diseases, announced today it has entered into a binding agreement to create an independent new company that combines Fresenius Health Partners, the value-based care division of Fresenius Medical Care North America, with InterWell Health, the l…

Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer Paris, March 16, 2022. Sanofi and Seagen Inc. (Nasdaq:SGEN) today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein and Sanofi currently has one ADC in development. John Reed, M.D., Ph.D.Global Head of Research and Development, Sanofi“This collaboration will enable the synergistic combination of molecules and platforms to produce candidate medicines with th…

NORTH CHICAGO, Ill., March 15, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Scripps Research, an independent, non-profit biomedical research and drug discovery institute, today announced a global collaboration to develop potential novel, direct-acting antiviral treatments for COVID-19. "Constant change is something we've experienced throughout the COVID-19 pandemic, with the emergence of many new variants and the evolving needs of treatment options to combat more contagious, aggressive and severe strains of the virus," said Tom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. "We are committed to bringing differentiated, next generation oral antiviral treatments to patients and ensuring broad access to address the diverse treatment needs around the world." Th…

Investment will accelerate the overall Sarclisa® development program Sanofi will continue to fully manage the clinical program and retain full rights and control of Sarclisa® (isatuximab) PARIS, March 15, 2022. Sanofi and Blackstone (NYSE: BX) today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa®, to treat patients with multiple myeloma (MM). If successful, BXLS will be eligible to receive royalties on future subcutaneous sales. The pivotal study for the subcutaneous formulation is expected to begin in the second half of 2022. For the…

GAITHERSBURG, MD, March 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center and part of NYU Langone Health. The collaboration is centered around NexImmune’s artificial antigen presenting cells' (aAPCs) ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients. Dr. Jeffrey S. Weber, Deputy Director of the Laura and Isaac Perlmutter Cancer Center will guide the research and evaluat…

NORTH CHICAGO, Ill. and BUDAPEST, Hungary, March 11, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development. AbbVie and Richter have collaborated for 15 years on Central Nervous System (CNS) projects, including globally launched products such as cariprazine (VRAYLAR® / REAGILA®). "In collaboration with Richter, we will continue to build on our research that seeks to provide additional insights into our understanding of caripra…

Digital Diagnostics and Baxter International Inc. announced a long-term strategic partnership to help front line care providers deliver high-quality care and improve care outcomes. The partnership includes plans to offer Digital Diagnostics’ industry-leading IDx-DR® autonomous AI software as a diagnostic service combined with the Welch Allyn® RetinaVue® 700 Imager.  Digital Diagnostics created IDx-DR, the autonomous AI diagnostic system for the detection of diabetic retinopathy (including diabetic macular edema) at the point-of-care. Only 15% of people with diabetes receive the recommended annual diabetic eye exam.1,2 Access to effective diagnostic services is an obstacle, especially in rural or underserved areas. It leaves many with undiagnosed and untreated levels of disease, and a highe…

BioNTech and Regeneron plan to jointly conduct clinical trials evaluating FixVac candidate BNT116 in combination with Libtayo for the treatment of advanced non-small cell lung cancer (NSCLC) The development costs for the trials will be equally shared between the parties The companies advance clinical development of FixVac and Libtayo combination to third tumor type building on their existing agreements in melanoma and prostate cancer by combining their complementary immunotherapies to pave the way for new treatment options in high medical need indications MAINZ, Germany, March 8, 2022 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the expansion of its strategic collaboration with Regeneron to advance the Company’s FixVac candidate BNT116 in co…

As the Covid-19 pandemic continues to have a disproportionate impact on women, Organon invites other organisations to join them in their mission to adopt initiatives which help women prioritise their health. LONDON, UK — Organon (NYSE: OGN), a global women’s health company, is designating International Women’s Day (IWD) on 8th March as a day to recognise the growing health disparities that women face that have been exacerbated by the COVID-19 pandemic. Since its inception, IWD has focused on accelerating gender parity. Organon recognises the need for a global effort to address her health and understands that it needs to start with its own employees by giving them paid time off to attend to their own health needs. The company is also inviting organisations in the UK and across the globe to…

Moderna announces commitment to advance vaccines targeting 15 pathogens identified as biggest public health risk by WHO and CEPI into clinical studies by 2025 Moderna launches mRNA Access, a new collaborative enabling researchers around the world to utilize Moderna's mRNA technology platform to pursue research in their own labs on emerging and neglected infectious diseases Moderna expands commitment to never enforce COVID-19 patents in the Gavi COVAX AMC for 92 low- and middle-income countries Moderna has entered into a Memorandum of Understanding with the Government of the Republic of Kenya to establish its first mRNA manufacturing facility on the continent of Africa CAMBRIDGE, MA / ACCESSWIRE / March 7, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RN…

Acquires Swiss-based multi-disciplinary consultancy SFL (Solutions for Life Sciences) to accelerate the development of and access to innovative treatments SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, a scientific-minded global clinical research organization (CRO), announced today the expansion and strengthening of its service capabilities by acquiring SFL (Solutions for Life Sciences). With headquarters in Basel, Switzerland and several European affiliates, SFL brings unique capabilities and a highly credentialed team to support a growing number of biotech, pharmaceutical and medtech companies. Led by Founder and CEO Shayesteh Fürst-Ladani, the SFL team has longstanding experience in providing strategic advice and operational support for all stages of product development, with in-house…

Pharma and biotech customers distinguish excellence in capabilities, expertise, quality, compatibility, reliability and service Waltham, Mass. (March 3, 2022) – For the third consecutive year, Thermo Fisher Scientific’s pharma and biopharma customers recognized its contract manufacturing leadership in all six categories of the 11th Annual CMO Leadership awards. The annual honors, presented by Life Science Leader and Outsourced Pharma, spotlight excellence in Capabilities, Expertise, Quality, Compatibility, Reliability and Service. The customers evaluated 86 companies across 23 performance metrics. "Patients worldwide need treatments sooner than ever so we need to exceed our customers’ expectations every day,” said Mike Shafer, senior vice president and president, pharma servi…

WILMINGTON, N.C. (March 2, 2022) –Thermo Fisher Scientific’s PPD clinical research business has been named a winner in Training magazine’s 2022 Training APEX Awards, recognizing its robust enterprise learning programs designed to grow employees’ skills and drive customers’ success. As part of Thermo Fisher’s commitment to talent development, the PPD clinical research business designs, develops and deploys a wide range of employee learning and performance programs, providing ongoing training and development that engages employees for optimal performance, leverages technology, develops staff and measures outcomes. “We are honored to win this award for the 11th consecutive year from the highly regarded team at Training magazine,” said Jay Dixon, senior vice president, quality and enterprise l…

- Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies- Novel mechanism will be evaluated for the potential to mitigate synaptic dysfunction associated with cognitive deficits across a range of neuropsychiatric and neurodegenerative disorders NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. The mechanism is currently being evaluated for the potential tre…

Boehringer Ingelheim partners with Lifebit Biotech, Ltd. to build a scalable data, analytics, and infrastructure platform This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine The leading research-driven biopharmaceutical company Boehringer Ingelheim and precision medicine software company Lifebit Biotech, Ltd. (Lifebit) today announce partnership in which Lifebit will support Boehringer Ingelheim in building a scalable data, analytics, and infrastructure platform within its IT environment.  “This platform will play an important part of Boehringer Ingelheim’s broader strategy to capture translational disease insights from large external healthcare biobanks and u…

Today, 28 February 2022, is Rare Disease Day; the day dedicated to raising awareness for the 300 million people living with a rare disease around the world.  Across the globe, the rare disease community and its supporters are coming together today to share their colours and call for more equitable access to social opportunity, treatment and care for people living with a rare disease and their families. Thousands of events including building illuminations, fundraisers, sporting events, scientific conferences, art exhibitions, policy events and much more are taking place today in over 100 countries! Take a look at the interactive world map of Rare Disease Day events. As part of the Rare Disease Day 2022 campaign, we highlight the stories of 16 superheroes whose experiences represent many of…

Voluntis Announces Partnership with Tilak Healthcare to Help Patients with Cancer Better Manage Ocular Toxicities Cambridge, Massachusetts, February 23, 2022 - Voluntis, an Aptar Pharma company and leader in digital therapeutics, today announced a partnership with Tilak Healthcare, a digital therapeutics company specializing in clinically validated medical mobile apps for chronic diseases. Under this new collaboration, both companies will combine Tilak’s OdySight® Care™ mobile app with Voluntis’ Theraxium platform to offer a vision-screening solution for patients living with cancer. This new solution will give patients of Voluntis’ digital therapeutics (DTx) platform access to OdySight® Care™ and the possibility to measure their visual health anytime and anywhere. Once they have tested the…